Enclomiphene vs Clomiphene: What the Research Compares

The short version

Enclomiphene and clomiphene are not two unrelated drugs. Clomiphene citrate is a mixture of two geometric isomers, enclomiphene and zuclomiphene, and the published pharmacology literature has characterised enclomiphene as the estrogen receptor antagonist component of that mixture (PMID 19204885, PMID 19938905). Comparing them is therefore a comparison between a two-isomer mixture and one isolated isomer of it, rather than between two chemically distinct molecules.

Direct head-to-head data in men are limited. One retrospective study compared clomiphene citrate with enclomiphene citrate in male infertility treatment (PMID 37546076), and recent evidence syntheses have assessed the two agents together in hypogonadal men (PMID 39434750, PMID 41066380). Beyond those, most of the evidence consists of separate literatures that have to be read side by side. This page is for educational purposes only and is not medical advice; consult a licensed physician about whether any prescription medicine is appropriate for a given person.

Class and chemistry

Both agents belong to the selective estrogen receptor modulator (SERM) class, a group reviewed in the context of male hypogonadism by a 2022 clinical inquiry in family practice literature (PMID 35259334). Clomiphene citrate contains enclomiphene (the trans isomer) and zuclomiphene (the cis isomer), and reviews of hypogonadal androgen deficiency have described the two isomers as having different pharmacological character within the mixture (PMID 19938905).

That isomer split matters to the comparison because the two components do not behave identically over time. Researchers who measured serum levels of enclomiphene and zuclomiphene in men on long-term clomiphene citrate treatment reported on the relative circulating concentrations of each isomer in that setting (PMID 27511863). The rationale repeatedly stated in enclomiphene reviews is that isolating the antagonist isomer removes the other isomer from the exposure profile (PMID 27337642, PMID 19204885).

Mechanism as described in the literature

Both agents are described as acting at the level of the hypothalamic–pituitary axis rather than by supplying exogenous androgen. Enclomiphene has been characterised as an estrogen receptor antagonist used to address testosterone deficiency in men by stimulating endogenous production (PMID 19204885). A trial of oral enclomiphene citrate reported stimulation of endogenous testosterone production and measured sperm counts in men with low testosterone, with testosterone gel as the comparator (PMID 23530575). Reviews of clomiphene citrate in hypogonadal androgen deficiency have described the same general axis-stimulating approach for the mixture (PMID 19938905).

Regulatory status

Both substances are prescription medicines. Neither is a dietary supplement; both are prescription-only. Clomiphene citrate is a long-marketed approved prescription product, and its use in men has been discussed throughout the urology and family medicine literature as an off-label application of an existing drug (PMID 35259334, PMID 19938905).

Enclomiphene citrate has been discussed in the literature as an investigational agent for testosterone deficiency and secondary hypogonadism rather than as an approved product with a marketed label for that use (PMID 19204885, PMID 27337642). Regulatory status differs by country and changes over time; a prescribing clinician or pharmacist is the appropriate source for the current position in any jurisdiction. This page does not provide legal advice.

Head-to-head evidence

Direct comparisons are the most useful part of this question, and they are scarce.

Retrospective comparison in male infertility

A 2023 retrospective study examined the efficacy of clomiphene citrate versus enclomiphene citrate for male infertility treatment, placing the two agents in the same analysis rather than comparing across separate publications (PMID 37546076). Retrospective designs draw on records of care already delivered, so they do not randomise allocation and are subject to confounding by which patients were prescribed which agent.

Pooled and comparative reviews

A 2024 publication assessed the safety and efficacy of enclomiphene and clomiphene in hypogonadal men within a single review framework (PMID 39434750). A 2025 systematic review and meta-analysis gathered randomised controlled trials of clomiphene or enclomiphene citrate for male hypogonadism and analysed them together (PMID 41066380). These syntheses are the closest the literature currently comes to an organised comparison, and readers interested in effect estimates should consult the published papers and discuss them with a clinician rather than rely on a summary.

The separate evidence bases, side by side

What enclomiphene studies measured

The most frequently cited enclomiphene trial compared oral enclomiphene citrate with testosterone gel in men with low testosterone and reported on endogenous testosterone production and sperm counts (PMID 23530575). That comparator choice is important: it positions enclomiphene against exogenous testosterone therapy, not against clomiphene.

Review articles have summarised enclomiphene citrate in secondary male hypogonadism, including its pharmacology and the clinical rationale for a single-isomer agent (PMID 27337642). A 2019 review framed enclomiphene citrate specifically as a treatment approach intended to maintain fertility in men with secondary hypogonadism (PMID 31063005). Earlier coverage in the investigational drugs literature described enclomiphene as an estrogen receptor antagonist under development for testosterone deficiency (PMID 19204885).

What clomiphene studies measured

Clomiphene citrate has a much longer clinical history, and reviews have discussed its use in hypogonadal androgen deficiency alongside the isomer question (PMID 19938905). A clinical inquiry review asked directly whether SERMs are safe and effective for the treatment of hypogonadism in men and examined the available evidence for that question (PMID 35259334).

One pharmacokinetic observation specific to the mixture is the measurement of both isomers during extended use: researchers reported serum levels of enclomiphene and zuclomiphene in men on long-term clomiphene citrate treatment (PMID 27511863). This kind of data is often cited as the practical basis for distinguishing the mixture from the isolated isomer.

Adverse Events: What Studies Report

Safety has been assessed within the comparative reviews rather than in a dedicated head-to-head safety trial. The 2024 review evaluated safety as well as efficacy for enclomiphene and clomiphene in hypogonadal men (PMID 39434750), and the 2025 systematic review and meta-analysis of randomised controlled trials examined both agents in male hypogonadism (PMID 41066380). The question of whether SERMs are safe and effective in this population was also addressed directly in a 2022 review (PMID 35259334).

One preclinical signal sits outside the clinical literature entirely. A study in zebrafish reported that clomiphene citrate and enclomiphene hydrochloride exposure was associated with interfrontal suture fusion, a craniofacial developmental outcome (PMID 37915340). Animal-model findings of this kind do not translate directly to humans, but they are part of the published record for both compounds and are relevant context for anyone discussing reproductive-stage exposure with a clinician.

Research outside the hormone literature

Both the mixture and its isomers have been examined for unrelated pharmacology. An in vitro virology study reported that clomiphene and its isomers blocked Ebola virus particle entry and infection with similar potency (PMID 27490565). That work has no bearing on hormonal use in men and is cited here only to show that the isomer distinction has been studied in more than one biological context.

What the comparison cannot currently settle

• Long-term outcomes. The reviews that assessed both agents focused on hypogonadal endpoints within the trials available to them (PMID 41066380, PMID 39434750).
• Design quality of direct comparisons. The one published head-to-head efficacy comparison in male infertility was retrospective rather than randomised (PMID 37546076).
• Comparator mismatch. The best-known enclomiphene trial used testosterone gel, not clomiphene, as its comparator (PMID 23530575).
• Isomer-specific clinical consequences. Serum isomer concentrations during long-term clomiphene use have been measured (PMID 27511863), but mapping those measurements onto patient-level differences remains a clinical judgement.

Questions a clinician is positioned to answer

1. Whether the underlying diagnosis is secondary hypogonadism, which is the population described in the enclomiphene review literature (PMID 31063005, PMID 27337642).
2. Whether fertility preservation is a stated goal, since that framing appears in both the enclomiphene and infertility comparison literature (PMID 37546076).
3. What the current approval and prescribing status of each agent is in the relevant country.
4. What monitoring the reviewed evidence base implies for safety assessment (PMID 35259334).

No part of this page should be read as a recommendation of one agent over the other. The literature summarised here describes what investigators measured; it does not establish what any individual should do. Decisions about prescription medicines belong with a licensed prescribing clinician who can review the full published data alongside a person's own history.

References

• Safety and efficacy of enclomiphene and clomiphene for hypogonadal men (Translational Andrology and Urology, 2024)
• Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials (Archives of Endocrinology and Metabolism, 2025)
• Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men (IDrugs, 2009)
• Enclomiphene citrate for the treatment of secondary male hypogonadism (Expert Opinion on Pharmacotherapy, 2016)
• Clomiphene Citrate and Enclomiphene Hydrochloride Exposure Is Associated With Interfrontal Suture Fusion in Zebrafish (Plastic Surgery, 2023)
• Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism (Expert Review of Endocrinology & Metabolism, 2019)
• Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study (Cureus, 2023)
• Are SERMs safe and effective for the treatment of hypogonadism in men? (The Journal of Family Practice, 2022)
• Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel (The Journal of Sexual Medicine, 2013)
• Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment (BJU International, 2017)
• Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency (Expert Opinion on Investigational Drugs, 2009)
• Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications (Viruses, 2016)